Phosphodiesterase type 5 inhibitor use does not affect heart failure hospitalizations in patients with left ventricular assist devices
Journal of Cardiac Failure Aug 19, 2017
Hassanein MT, et al. – This study investigated the ability of type 5 phosphodiesterase (PDE5) inhibitor in attenuating the rate of post– implantation heart failure hospitalizations in patients implanted with an left ventricular assist devices (LVAD). Findings reported no impact of PDE5 inhibitor on rate of heart failure hospitalization in this population.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
